SANTA ANA, Calif., Sept. 17, 2025 /PRNewswire/ — Stanford Advanced Materials (SAM) is pleased to announce the launch of a new series of optical and nonlinear crystals. The new series will target meeting the growing and diverse demands of photonics, laser research, and high-precision optical applications. SAM continues to demonstrate its commitment to innovation, quality, and tailored solutions for global customers.

SAM introduces five exclusive additions to the catalogue range: PPLN, MGLN, BIBO, CaF₂, and PPKTP.

PPLN (Periodically Poled Lithium Niobate)

PPLN delivers high-efficiency nonlinear wavelength conversion, with a broad transparency range from 350–5200 nm and versatile quasi-phase-matching structures. Its high nonlinear coefficient and stable performance under controlled temperatures make it ideal for compact, cost-effective laser systems and precision photonics setups. Typical applications include SHG, OPO, DFG, SFG, and quantum optics experiments.

MGLN (Magnesium-Doped Lithium Niobate)

MGLN features a high optical damage threshold, low absorption loss, stable refractive index, and broad transparency, making it ideal for room-temperature phase matching. It is well suited for optical modulation, wavelength conversion, high-power lasers, telecommunications, and nonlinear optical devices.

BIBO (Bismuth Borate)

BIBO offers a large effective nonlinear coefficient (3.5–4× LBO, 1.5–2× BBO, ~8× KDP) and high damage threshold, supporting efficient frequency conversion in the visible and blue ranges. It performs well in second-harmonic generation, optical parametric oscillators, and amplifiers.

CaF₂ (Calcium Fluoride)

CaF₂ provides broad transmission from ultraviolet to infrared wavelengths, with low dispersion and high optical clarity. It is commonly used in lenses, windows, prisms, and high-resolution imaging or spectroscopic systems.

PPKTP (Periodically Poled Potassium Titanyl Phosphate)

PPKTP is a nonlinear crystal with a periodically poled structure that provides efficient quasi-phase matching and a nonlinear coefficient three times higher than standard KTP. It is used for SHG, quantum optics experiments, and generating entangled photons across KTP’s transparency range.

With this expansion, SAM reinforces its role as a trusted supplier of advanced crystal materials. The portfolio offers both technical excellence and flexible customization, supporting diverse research and industrial requirements. These crystals provide the foundation for next-generation photonics and laser technologies.

About Stanford Advanced Materials

Founded in 1994, Stanford Advanced Materials (SAM) is a U.S.-based provider of over 7,000 advanced materials to aerospace, technology, medical, and other high-performance markets. Headquartered in Santa Ana, California, SAM utilizes technical proficiency and a worldwide supply chain to deliver reliable, scalable solutions globally.

HONG KONG, Sept. 17, 2025 /PRNewswire/ — On September 11, Blue Planet Environmental Solutions, a leading force in sustainable waste management, took centre stage at the AVPN Global Conference 2025 in Hong Kong, showcasing how bold bets on circular economy innovation are reshaping Asia’s environmental future.

Delivering a powerful message under the Social Innovation Track, Prashant Singh, Co-Founder & CEO of Blue Planet, shared the company’s journey from an unconventional idea to a tech-powered platform integrating municipal solid waste, e-waste, plastics, hazardous waste, and biofuels—a first in the industry.

“When we started, no one imagined waste could be reimagined as a single integrated platform. Everyone worked in silos. We bet on circularity, traceability, and zero waste to landfill before it was mainstream. Today, that bet is reality,” Singh said.

He spotlighted Blue Planet’s landfill mining projects, at scale in India, once deemed impossible, now reclaiming hundreds of acres of toxic dumps through technology and public-private partnerships.

“Leadership is not about avoiding risk—it’s about making risk investible, bankable, and scalable,” Singh noted.

Singh also underlined the need for patient, risk-aligned capital and progressive policies to scale circular models, while reaffirming Blue Planet’s commitment to radical transparency, last-mile traceability, and on-ground empowerment as the company’s cultural backbone.

“We don’t sell disruption. We build trust with data, transparency, and impact. Every ton processed, every acre reclaimed, is tracked and verified,” he added.

The AVPN Global Conference 2025, hosted with The Hong Kong Jockey Club Charities Trust, convened over 250 speakers and 100 sessions on climate action, sustainable finance, and inclusive development.

Blue Planet’s participation reinforced its mission: transforming waste into value and pioneering scalable circular economy solutions across Asia.

About Blue Planet

Founded in 2017, Blue Planet is a Singapore headquartered company pioneering regional sustainability through technology-driven and IP-based end-to-end solutions for waste management and upcycling. The company has successfully created an innovative technology driven end-to-end waste management platform. The mission is to apply these technologies across various stages of the waste life cycle. Blue Planet is committed to provide circular economy solutions and achieve its vision of zero waste to landfill.

To learn more about Blue Planet, visit: www.blueplanet.asia

About AVPN

AVPN is the largest network of social investors in Asia, comprising over 600 funders and resource providers across 33 markets. Our mission is to increase the flow and effectiveness of financial, human, and intellectual capital in Asia by enabling members to channel resources towards impact. As an ecosystem builder, AVPN enables its members to connect, learn, act, and lead social impact efforts across key pillars while improving the effectiveness of deployed capital, bringing local field needs, regional expertise, and policy insights to the forefront.

For more information about AVPN and our work, please visit: avpn.asia/

NEW YORK, Sept. 17, 2025 /PRNewswire/ — The New York Stock Exchange (NYSE) provides a daily pre-market update directly from the NYSE Trading Floor. Access today’s NYSE Pre-market update for market insights before trading begins. 

Ashley Mastronardi delivers the pre-market update on September 17th

• Stocks are mixed this morning ahead of the Federal Reserve’s highly anticipated decision on interest rates this afternoon at 2 PM ET. Shortly thereafter, Chair Jerome Powell will deliver remarks
• According to the latest data, traders are pricing in a more than 95% chance that the Federal Reserve will cut interest rates by 25-basis points to a range of 4.25%. This would mark the Fed’s first interest rate cut since last December.
• Global online ticket marketplace StubHub celebrates its IPO today. On Tuesday, StubHub priced its IPO at $23.50 per share, valuing the company at $8.6 billion. It will begin trading under the ticker symbol STUB.

Opening Bell
StubHub (NYSE: STUB) celebrates its initial public offering

Closing Bell
Garmin (NYSE: GRMN) celebrates the 2025 Garmin Health Summit

Click here to download the NYSE TV App

Video – https://mma.prnasia.com/media2/2775400/NYSE_Market_Update_Sept_17.mp4

NEW YORK, Sept. 17, 2025 /PRNewswire/ — Bullish (NYSE: BLSH), an institutionally focused global digital asset platform that provides market infrastructure and information services, today announced that its U.S. digital asset trading and custody business, Bullish US Operations LLC, has been granted a BitLicense and Money Transmission License by the New York State Department of Financial Services (NYDFS). The license, officially defined as a ‘Virtual Currency Business Activity License’ by the NYDFS, allows Bullish to provide institutions and advanced traders in New York State digital asset spot trading and custody services. This is another key step in the expansion of Bullish’s global regulatory footprint.

“New York is widely recognized as being at the forefront of virtual currency regulation. Receiving our BitLicense and Money Transmission License from the New York Department of Financial Services is a testament to Bullish’s commitment to regulatory compliance and our dedication to building trusted, institutional-grade digital asset infrastructure in key global markets,” said Tom Farley, CEO of Bullish. “As a former President of the New York Stock Exchange and a proud New Yorker, I look forward to Bullish’s contribution to the city’s thriving financial ecosystem.”

“Securing the New York BitLicense is a significant regulatory milestone for our growth in the U.S. and also signals our credibility to operate within the financial capital of the world,” said Chris Tyrer, President of Bullish Exchange. “We believe that clear regulation drives responsible market evolution and institutional engagement. We look forward to offering New York’s institutions and advanced traders Bullish’s regulated, high-performance digital asset services.”

Prospective institutional customers and advanced traders in New York State and elsewhere in the U.S. who are eager to onboard are encouraged to get in touch with a Bullish relationship manager.

Media: media@bullish.com

About Bullish

Bullish is an institutionally focused global digital asset platform that provides market infrastructure and information services. These include: Bullish Exchange – a regulated and institutionally focused digital assets spot and derivatives exchange, integrating a high-performance central limit order book matching engine with automated market making to provide deep and predictable liquidity. Bullish Exchange is regulated in the United States, European Union, Hong Kong, and Gibraltar. CoinDesk Indices – a collection of tradable proprietary and single-asset benchmarks and indices that track the performance of digital assets for global institutions in the digital assets and traditional finance industries. CoinDesk Data – a broad suite of digital assets market data and analytics, providing real-time insights into prices, trends, and market dynamics. CoinDesk Insights – a digital asset media and events provider and operator of Coindesk.com, a digital media platform that covers news and insights about digital assets, the underlying markets, policy, and blockchain technology. For more information, please visit bullish.com and follow LinkedIn and X.

Use of Websites to Distribute Material Company Information

We use the Bullish Investor Relations website (investors.bullish.com) and our X account (x.com/bullish) to publicize information relevant to investors, including information that may be deemed material, in addition to filings we make with the U.S. Securities and Exchange Commission (SEC) and press releases. We encourage investors to regularly review the information posted on our website and X account in addition to our SEC filings and press releases to be informed of the latest developments.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Sentences containing words such as “believe,” “intend,” “plan,” “may,” “expect,” “should,” “could,” “anticipate,” “estimate,” “predict,” “project,” or their negatives, or other similar expressions of a future or forward-looking nature generally should be considered forward-looking statements and include, without limitation, statements relating to future events or Bullish’s future financial or operating performance, business strategy, and potential market opportunity, including in the United States. Such forward-looking statements are based upon estimates and assumptions that, while considered reasonable by Bullish, are inherently uncertain and are subject to risks, uncertainties, and other factors which could cause actual results to differ materially from those expressed or implied by such forward-looking statements. Factors that may cause results to differ from those expressed in our forward-looking statements include, but are not limited, to our ability to grow our business and operations, including in new geographic locations, the costs or expenditures associated therewith, competition in our industry, and the evolving rules and regulations applicable to digital assets and our industry. You should not place undue reliance on any such forward-looking statements, which speak only as of the date they are made, and Bullish undertakes no duty to update these forward-looking statements.

SKY-0515 achieves dose-dependent reductions of mutant huntingtin (mHTT) protein, with 62% lowering at Day 84 on the 9mg daily oral dose

Additional findings include dose-dependent reductions in PMS1 mRNA, excellent brain penetration, and a favorable safety profile

SKY-0515’s Phase 2/3 FALCON-HD trial in patients in Australia and New Zealand is ongoing 

BOSTON, Sept. 17, 2025 /PRNewswire/ — Skyhawk Therapeutics, Inc., a clinical-stage biotechnology company developing novel small molecule therapies designed to modulate critical RNA targets, today announced positive results from the first interim analysis of the Part C patient cohort in its Phase 1 clinical trial of SKY-0515, an investigational treatment for Huntington’s disease (HD). At Day 84, patients receiving SKY-0515 demonstrate dose-dependent reductions of mHTT protein in blood including 62% at the 9mg dose. SKY-0515 has been generally well tolerated at both dose levels tested. 

Reduction in mHTT protein level in blood from pre-dose through 84 days of treatment. — Skyhawk Therapeutics, Inc. ‘Phase 1 Part C patient cohort reduction in mHTT protein level in blood at Day 84,’ 2025; Note: Error bars represent standard error of the mean. Placebo (N=6), 3mg (N=10), and 9mg (N=10) patient treatment is ongoing. (PRNewsFoto/Skyhawk Therapeutics)

Treatment with SKY-0515 also results in important dose-dependent PMS1 mRNA reduction and demonstrates excellent central nervous system penetration. The overall safety profile has been favorable, supporting the continued clinical development of the program.

“SKY-0515 is reducing mHTT protein to the most impressive extent we’ve seen so far in patients, and crucially the clinical and biomarker data show no safety concerns so far at any dose tested,” said Ed Wild, Professor of Neurology at University College London. “It is great that we are seeing substantial PMS1 reduction as well, which should be a potent combination for treating Huntington’s disease via two of its core pathogenic mechanisms. This is what success looks like at the 3-month timepoint, setting the stage for meaningful impact for people living with HD across the world – for whom an orally administered huntingtin-lowering treatment such as SKY-0515 would be truly transformative.”

“The strength of SKY-0515’s biomarker response after just 84 days of treatment underscores its potential as a transformative therapy for HD,” said Sergey Paushkin, Head of R&D at Skyhawk Therapeutics. “These interim data represent an important milestone for SKY-0515 and highlight the power of Skyhawk’s platform to deliver first-in-class small molecules for devastating diseases with no approved disease-modifying therapies.”

Huntington’s disease is a rare, hereditary, and ultimately fatal neurodegenerative disorder that affects over 40,000 symptomatic patients in the United States, with hundreds of thousands estimated to be affected worldwide. There are currently no approved treatments which slow or halt disease progression. SKY-0515 is Skyhawk’s orally-administered, investigational small molecule RNA splicing modifier developed through the company’s novel RNA-splicing platform, SKYSTAR^®.  SKY-0515 is designed to reduce both HTT protein and PMS1 protein, an additional key driver of somatic CAG repeat expansion and HD pathology.

SKY-0515 was developed through Skyhawk’s proprietary integrated platform, SKYSTAR^®, and is the first Skyhawk drug in clinical trials. 

Skyhawk expects to put a series of additional novel drugs to treat rare neurological diseases with no presently approved disease modifying therapies in the clinic by the end of 2027. The first is on track to initiate trials in mid-2026.

About SKY-0515’s Phase 1 Clinical Study
SKY-0515’s Phase 1 clinical trial is a first-in-human trial designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics, specifically blood biomarker modulation activity, of SKY-0515 in healthy volunteers and individuals with early-stage Huntington’s disease (HD). The trial is separated into three parts. Parts A and B evaluated SKY-0515 in Healthy Volunteers. Part C is a double-blind placebo-controlled parallel design study of two dose levels of SKY-0515 and placebo of individuals with early-stage HD (HD-ISS Stage 1, 2, or mild Stage 3) for 84 days followed by a 12 month extension of active treatment where all participants will receive either a low or high dose of SKY-0515 in a blinded fashion. The objectives of the study are to evaluate safety, pharmacokinetic, and pharmacodynamic parameters including mutant HTT protein and PMS1 mRNA. Part C enrollment is complete, and topline data from the blinded active treatment extension are expected in mid-2026.

About SKY-0515’s Phase 2/3 FALCON-HD Clinical Study
FALCON-HD (NCT06873334) is a Phase 2/3 randomized, double-blind, placebo-controlled, dose ranging study to evaluate the pharmacodynamics, safety, and efficacy of SKY-0515 in 120 participants with Stage 2 and early Stage 3 HD across 10 sites in Australia and New Zealand. Eligible patients will receive a once-daily oral dose of SKY-0515 at one of three dose levels, or placebo, for a treatment period of at least 12 months. The trial aims to assess the potential of SKY-0515 to modulate RNA splicing and reduce mHTT and PMS1 proteins, which are implicated in the pathology of Huntington’s disease. Additional information about FALCON-HD, including participating sites and eligibility criteria, can be found at ClinicalTrials.gov and www.FALCON-HD.com.

About Skyhawk Therapeutics
Skyhawk Therapeutics is a clinical-stage biotechnology company which uses its proprietary platform, SKYSTAR^®, to discover and develop small molecule RNA modulating therapies for the world’s most intractable diseases. For more information visit www.skyhawktx.com.  

Skyhawk Contact
Maura McCarthy
maura@skyhawktx.com